发布求助
文献互助 智能选刊 最新文献

Future Virology最新文献

筛选
英文 中文
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes. DPP-4抑制剂作为COVID-19糖尿病患者的救星
IF 3.1 4区 医学
Future Virology Pub Date : 2023-03-01 DOI: 10.2217/fvl-2022-0112
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
{"title":"DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.","authors":"Snehasish Nag,&nbsp;Samanwita Mandal,&nbsp;Oindrila Mukherjee,&nbsp;Suprabhat Mukherjee,&nbsp;Rakesh Kundu","doi":"10.2217/fvl-2022-0112","DOIUrl":"https://doi.org/10.2217/fvl-2022-0112","url":null,"abstract":"<p><p>Diabetic patients are at particular risk of severe COVID-19. Human dipeptidyl peptidase-4 (DPP-4) is a membrane-bound aminopeptidase that regulates insulin release by inactivating incretin. DPP-4 inhibitors (DPP-4is) are therefore used as oral anti-diabetic drugs to restore normal insulin levels. These molecules also have anti-inflammatory and anti-hypertension effects. Recent studies on the interactions of SARS-CoV-2 spike glycoprotein and DPP-4 predict a possible entry route for SARS-CoV-2. Therefore, DPP-4is could be effective at reducing the virus-induced 'cytokine storm', thereby ceasing inflammatory injury to vital organs. Moreover, DPP-4is may interfere with viral entry into host cells. Herein, we have reviewed the efficacy of DPP-4is as potential repurposed drugs to reduce the severity of SARS-CoV-2 infection in patients with diabetes.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9321832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Efficiency rating of SG Diagnostics COVID-19 antigen rapid test kit. SG Diagnostics新冠病毒抗原快速检测试剂盒效率评价。
IF 3.1 4区 医学
Future Virology Pub Date : 2023-03-01 DOI: 10.2217/fvl-2021-0210
Francesco Chirico, Murat Yıldırım, Tomasz Dzieciatkowski, Marek Dabrowski, Marek Malysz, Marcin Madziala, Milosz Jaroslaw Jaguszewski, Karol Bielski, Gabriella Nucera, Krzysztof J Filipiak, Lukasz Szarpak
{"title":"Efficiency rating of SG Diagnostics COVID-19 antigen rapid test kit.","authors":"Francesco Chirico,&nbsp;Murat Yıldırım,&nbsp;Tomasz Dzieciatkowski,&nbsp;Marek Dabrowski,&nbsp;Marek Malysz,&nbsp;Marcin Madziala,&nbsp;Milosz Jaroslaw Jaguszewski,&nbsp;Karol Bielski,&nbsp;Gabriella Nucera,&nbsp;Krzysztof J Filipiak,&nbsp;Lukasz Szarpak","doi":"10.2217/fvl-2021-0210","DOIUrl":"https://doi.org/10.2217/fvl-2021-0210","url":null,"abstract":"<p><p><b>Aim:</b> Rapid detection is crucial in complementing vaccination to reduce transmission of SARS-CoV-2. <b>Materials & methods:</b> Nasopharyngeal swabs (n = 213) and oropharyngeal swabs (n = 98) were tested. with the antigen rapid test kit. <b>Results:</b> Overall sensitivity (97.96%), specificity (100.00%) and coincidence rate (98.71%) were high, which translated into a positive predictive value of 100.00% and a negative predictive value of 96.64%. <b>Conclusion:</b> Antigen rapid tests have a great potential for screening in different settings to deliver results with high sensitivity and specificity.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
In silico analysis of ACE2 from different animal species provides new insights into SARS-CoV-2 species spillover. 不同动物物种ACE2的计算机分析为SARS-CoV-2物种溢出提供了新的见解。
IF 3.1 4区 医学
Future Virology Pub Date : 2023-03-01 DOI: 10.2217/fvl-2022-0187
Felipe Pantoja Mesquita, Pedro Filho Noronha Souza, Dyane Rocha Aragão, Expedito Maia Diógenes, Emerson Lucena da Silva, Jackson Lima Amaral, Valder Nogueira Freire, Débora de Souza Collares Maia Castelo-Branco, Raquel Carvalho Montenegro
{"title":"<i>In silico</i> analysis of <i>ACE2</i> from different animal species provides new insights into SARS-CoV-2 species spillover.","authors":"Felipe Pantoja Mesquita,&nbsp;Pedro Filho Noronha Souza,&nbsp;Dyane Rocha Aragão,&nbsp;Expedito Maia Diógenes,&nbsp;Emerson Lucena da Silva,&nbsp;Jackson Lima Amaral,&nbsp;Valder Nogueira Freire,&nbsp;Débora de Souza Collares Maia Castelo-Branco,&nbsp;Raquel Carvalho Montenegro","doi":"10.2217/fvl-2022-0187","DOIUrl":"https://doi.org/10.2217/fvl-2022-0187","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to analyze the phylogenetic relationships between the ACE2 of humans and other animals and investigate the potential interaction between SARS-CoV-2 RBD and ACE2 of different species. <b>Materials & methods:</b> The phylogenetic construction and molecular interactions were assessed using computational models. <b>Results & conclusion:</b> Despite the evolutionary distance, 11 species had a perfect fit for the interaction between their ACE2 and SARS-CoV-2 RBD (<i>Chinchilla lanigera, Neovison vison</i>, <i>Rhinolophus sinicus, Emballonura alecto</i>, <i>Saccopteryx bilineata</i>, <i>Numida meleagris</i>). Among them, the avian <i>N. meleagris</i> was reported for the first time in this study as a probable SARS-CoV-2 host due to the strong molecular interactions. Therefore, predicting potential hosts for SARS-CoV-2 for understanding the epidemiological cycle and proposal of surveillance strategies.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9321831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evidence-based policies in public health to address COVID-19 vaccine hesitancy. 基于证据的公共卫生政策解决COVID-19疫苗犹豫问题。
IF 3.1 4区 医学
Future Virology Pub Date : 2023-03-01 Epub Date: 2023-04-04 DOI: 10.2217/fvl-2022-0028
Francesco Chirico, Jaime A Teixeira da Silva
{"title":"Evidence-based policies in public health to address COVID-19 vaccine hesitancy.","authors":"Francesco Chirico,&nbsp;Jaime A Teixeira da Silva","doi":"10.2217/fvl-2022-0028","DOIUrl":"10.2217/fvl-2022-0028","url":null,"abstract":"<p><p>A fundamental basis for effective health-related policymaking of any democratic nation should be open and transparent communication between a government and its citizens, including scientists and healthcare professionals, to foster a climate of trust, especially during the ongoing COVID-19 mass vaccination campaign. Since misinformation is a leading cause of vaccine hesitancy, open data sharing through an evidence-based approach may render the communication of health strategies developed by policymakers with the public more effective, allowing misinformation and claims that are not backed by scientific evidence to be tackled. In this narrative review, we debate possible causes of COVID-19 vaccine hesitancy and links to the COVID-19 misinformation epidemic. We also put forward plausible solutions as recommended in the literature.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10093330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex. SARS-CoV-2变异体受体结合域突变集对RBD-ACE2复合物稳定性的影响
IF 3.1 4区 医学
Future Virology Pub Date : 2023-03-01 DOI: 10.2217/fvl-2022-0152
Mykyta Peka, Viktor Balatsky
{"title":"The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex.","authors":"Mykyta Peka,&nbsp;Viktor Balatsky","doi":"10.2217/fvl-2022-0152","DOIUrl":"https://doi.org/10.2217/fvl-2022-0152","url":null,"abstract":"<p><p><b>Aim:</b> Bioinformatic analysis of mutation sets in receptor-binding domain (RBD) of currently and previously circulating SARS-CoV-2 variants of concern (VOCs) and interest (VOIs) to assess their ability to bind the ACE2 receptor. <b>Methods:</b> <i>In silico</i> sequence and structure-oriented approaches were used to evaluate the impact of single and multiple mutations. <b>Results:</b> Mutations detected in VOCs and VOIs led to the reduction of binding free energy of the RBD-ACE2 complex, forming additional chemical bonds with ACE2, and to an increase of RBD-ACE2 complex stability. <b>Conclusion:</b> Mutation sets characteristic of SARS-CoV-2 variants have complex effects on the ACE2 receptor-binding affinity associated with amino acid interactions at mutation sites, as well as on the acquisition of other viral adaptive advantages.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/65/fvl-2022-0152.PMC10089296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9321830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeting ‘immunogenic hotspots’ in Dengue and Zika virus: an in silico approach to a common vaccine candidate 针对登革热和寨卡病毒的“免疫原性热点”:一种常见候选疫苗的计算机方法
IF 3.1 4区 医学
Future Virology Pub Date : 2023-02-24 DOI: 10.2217/fvl-2022-0104
Dhrubajyoti Mahata, Debangshu Mukherjee, Kheerthana Duraivelan, Vanshika Malviya, P. Parida, G. Mukherjee
{"title":"Targeting ‘immunogenic hotspots’ in Dengue and Zika virus: an in silico approach to a common vaccine candidate","authors":"Dhrubajyoti Mahata, Debangshu Mukherjee, Kheerthana Duraivelan, Vanshika Malviya, P. Parida, G. Mukherjee","doi":"10.2217/fvl-2022-0104","DOIUrl":"https://doi.org/10.2217/fvl-2022-0104","url":null,"abstract":"Aim: Dengue and Zika viruses cause significant mortality globally. Considering high sequence similarity between the viral proteins, we designed common multi-epitope vaccine candidates against these pathogens. Methods: We identified multiple T and B cell epitope-rich conserved ‘immunogenic hotspots’ from highly antigenic and phylogenetically related viral proteins and used these to design the multi-epitope vaccine (MEV) candidates, ensuring high global population coverage. Results: Four MEV candidates containing conserved immunogenic hotspots from E and NS5 proteins with the highest structural integrity could favorably interact with TLR4-MD2 complex in molecular docking studies, indicating activation of TLR-mediated immune responses. MEVs also induced memory responses in silico, hallmarks of a good vaccine candidate. Conclusion: Conserved immunogenic hotspots can be utilized to design cross-protective MEV candidates.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41824120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Let’s make this go viral: welcome to your 18th dose of Future Virology 让我们让它像病毒一样传播开来:欢迎来到你的第18剂未来病毒学
IF 3.1 4区 医学
Future Virology Pub Date : 2023-02-03 DOI: 10.2217/fvl-2023-0002
Ellen Porter
{"title":"Let’s make this go viral: welcome to your 18th dose of Future Virology","authors":"Ellen Porter","doi":"10.2217/fvl-2023-0002","DOIUrl":"https://doi.org/10.2217/fvl-2023-0002","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45954481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease? 一个扭曲的错误信息:伊维菌素应该被批准作为COVID-19疾病的治疗药物吗?
IF 3.1 4区 医学
Future Virology Pub Date : 2023-02-01 DOI: 10.2217/fvl-2023-0006
Arman Shafiee, Mohammad Mobin Teymouri Athar, Sayed-Hamidreza Mozhgani
{"title":"A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?","authors":"Arman Shafiee,&nbsp;Mohammad Mobin Teymouri Athar,&nbsp;Sayed-Hamidreza Mozhgani","doi":"10.2217/fvl-2023-0006","DOIUrl":"https://doi.org/10.2217/fvl-2023-0006","url":null,"abstract":"<p><p>This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9465281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two sides of the same coin: the N-terminal and the receptor binding domains of SARS-CoV-2 Spike. 同一枚硬币的两面:SARS-CoV-2 Spike的n端和受体结合域。
IF 3.1 4区 医学
Future Virology Pub Date : 2023-02-01 DOI: 10.2217/fvl-2022-0181
Massimo Ciccozzi, Stefano Pascarella
{"title":"Two sides of the same coin: the N-terminal and the receptor binding domains of SARS-CoV-2 Spike.","authors":"Massimo Ciccozzi,&nbsp;Stefano Pascarella","doi":"10.2217/fvl-2022-0181","DOIUrl":"https://doi.org/10.2217/fvl-2022-0181","url":null,"abstract":"<p><p>The SARS-CoV-2 Spike receptor binding domain and N-terminal domain interact with each other in an intricate mechanism. Mutations modulate the interplay between the Spike and host molecules. This editorial comments on the intricacies of SARS-CoV-2 Spike interactions.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9438255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Natural killer cells in COVID-19: from infection, to vaccination and therapy. COVID-19中的自然杀伤细胞:从感染到疫苗接种和治疗。
IF 3.1 4区 医学
Future Virology Pub Date : 2023-02-01 DOI: 10.2217/fvl-2022-0040
Alireza Zafarani, Mohammad Hossein Razizadeh, Salar Pashangzadeh, Mohammad Reza Amirzargar, Mahsa Taghavi-Farahabadi, Mohammad Mahmoudi
{"title":"Natural killer cells in COVID-19: from infection, to vaccination and therapy.","authors":"Alireza Zafarani,&nbsp;Mohammad Hossein Razizadeh,&nbsp;Salar Pashangzadeh,&nbsp;Mohammad Reza Amirzargar,&nbsp;Mahsa Taghavi-Farahabadi,&nbsp;Mohammad Mahmoudi","doi":"10.2217/fvl-2022-0040","DOIUrl":"https://doi.org/10.2217/fvl-2022-0040","url":null,"abstract":"Natural killer (NK) cells are among the most important innate immunity members, which are the first cells that fight against infected cells. The function of these cells is impaired in patients with COVID-19 and they are not able to prevent the spread of the disease or destroy the infected cells. Few studies have evaluated the effects of COVID-19 vaccines on NK cells, though it has been demonstrated that DNA vaccines and BNT162b2 can affect NK cell response. In the present paper, the effects of SARS-CoV-2 on the NK cells during infection, the effect of vaccination on NK cells, and the NK cell-based therapies were reviewed.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9186944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信